Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
Conditions
Brief summary
This phase I/II trial studies the side effects of tozuleristide in imaging oral cavity squamous cell cancer and high-grade oral cavity dysplasia during surgery. Tozuleristide is an imaging agent that specifically binds to tumor cells. When exposed to near-infrared light, tozuleristide causes tumor cells to fluoresce (light up), so that surgeons may better distinguish tumor cells from healthy cells during surgery.
Detailed description
OUTLINE: Beginning 1 hour before surgery, patients receive tozuleristide intravenously (IV) over 1-5 minutes. Patients then surgical resection per standard of care and undergo near infrared (NIR) imaging with standard of care device.
Interventions
PROCEDURENear Infrared Imaging
Undergo NIR imaging
PROCEDURETherapeutic Conventional Surgery
Undergo surgery
DRUGTozuleristide
Given IV
Sponsors
University of Washington
Blaze Bioscience Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult subjects age \>= 18 years (yr) * Subjects must have suspected or confirmed oral cavity dysplasia or cT1-4 squamous cell carcinoma for which surgical excision is deemed clinically indicated by the treating physician. Histology confirmation not required prior to surgery * Able to provide written informed consent * If of child-bearing potential, agree to the continued use of 2 reliable forms of contraception from study enrollment through 30 days after receiving the study product. Male subjects must agree to use 2 reliable methods of contraception simultaneously for 30 days after receiving the study product if their partner is of child-bearing potential * Available for all study visits and able to comply with all study requirements
Exclusion criteria
* Known or suspected sensitivity to indocyanine green * In the opinion of the treating physician, subject has received photosensitizing medication that could interfere or confound study results * Any current medications with the potential to generate fluorescence or photochemical reaction * Enrolled in any other ongoing study * Currently lactating or breastfeeding * Positive pregnancy test or planning to become pregnant within 30 days (d) of receiving tozuleristide * Any current condition, including psychological and social situations which, in the opinion of the investigator, would impact adversely on the subject or the interpretation of the study data * Creatinine clearance \< 60 mL/min * Aspartate aminotransferase (AST) \> 1.5 x upper limit of normal (ULN) * Alanine aminotransferase (ALT) \> 1.5 x ULN * Bilirubin \> 1.5 x ULN
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Adverse Events (AEs) | 7-21 days after drug administration | Adverse events will be summarized as the number of each type of adverse event, per Criteria for Adverse Events version 5.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Without Tumor Fluorescence After Receiving Tozuleristide | Measured at time of surgery 1 to 30 hours after receiving tozuleristide | Number of subjects whose tumors did not show discernible fluorescence compared to background |
| Number of Participants for Which Negative Margins Were Achieved in Tozuleristide-guided Oral Cavity Tumor Excision | Surgery performed following tozuleristide injection 1-30 hours prior to surgery | To investigate the accuracy of tozuleristide fluorescent imaging in identifying tumor and achieving negative margins during excision of oral cavity squamous cell carcinoma and high-grade dysplasia. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATOREmily Marchiano
Fred Hutch/University of Washington Cancer Consortium
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 60.5 years |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 4 Participants |
| Smoking Current or former smokers | 6 Participants |
| Smoking Never smokers | 2 Participants |
| Subsite Buccal mucosa | 1 Participants |
| Subsite Floor of mouth | 1 Participants |
| Subsite Oral tongue | 5 Participants |
| Subsite Retromolar trigone | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 8 |
| other Total, other adverse events | 3 / 8 |
| serious Total, serious adverse events | 2 / 8 |
Outcome results
None listed